《2006CCO復(fù)發(fā)、轉(zhuǎn)移或持續(xù)性宮頸癌的化療》內(nèi)容簡(jiǎn)介：

    As part of a subgroup **ysis, median survival among patients not previouslytreated with cisplatin as a radiosensitizer was 15.4 months for patients treated withcisplatin and topotecan versus 8.8 months among patients treated with cisplatinalone. In those previously treated with cisplatin as a radiosensitizer, median survivalwas 7.9 months versus 5.5 months, respectively （p-values not reported）。

    《2006CCO復(fù)發(fā)、轉(zhuǎn)移或持續(xù)性宮頸癌的化療》內(nèi)容預(yù)覽：

    Carcinoma of the cervix is the third most common female genital tract malignancy in Canada,accounting for an estimated 1350 new cases and 400 deaths in 2005（1）。 Although the rate ofincidence has declined dramatically over the past decades, cervical cancer contributes to 510new cases and 160 deaths each year in Ontario alone （1）。 The prognosis for early-stagecervical cancer is good due to effective screening practices and early treatments involvingsurgery and radiotherapy （2）。 In patients with high-risk local disease or advanced disease, theuse of radiosensitizing chemotherapy, typically cisplatin, improves survival outcomes overradiotherapy alone and has become a standard of care （3）； however, five-year survival forpatients with recurrent or persistent cervical cancer is less than 5% （4）。 Due to the increasinguse of cisplatin as a radiosensitizer in primary therapy, the effectiveness of cisplatin alone or incombination for first-line treatment is not well defined for this patient population.

    點(diǎn)擊下載***：《2006CCO復(fù)發(fā)、轉(zhuǎn)移或持續(xù)性宮頸癌的化療》